Regulatory FDA delays verdict on Beren’s rare disease drug by three months BioSpaceBeren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17.Rare DiseaseRead full story pharminent May 29, 2026 (Last updated: May 30, 2026) BioSpace Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s InnoventNext: Replimune gives cancer immunotherapy a third try after FDA leadership shakeup Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
